

# BMJ Open NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study

Gwen M C Masclee,<sup>1,2</sup> Preciosa M Coloma,<sup>1</sup> Manon C W Spaander,<sup>2</sup> Ernst J Kuipers,<sup>2</sup> Miriam C J M Sturkenboom<sup>1,3</sup>

**To cite:** Masclee GMC, Coloma PM, Spaander MCW, *et al.* NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. *BMJ Open* 2015;**5**:e006640. doi:10.1136/bmjopen-2014-006640

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2014-006640>).

Received 15 September 2014

Revised 9 November 2014

Accepted 7 January 2015



CrossMark

For numbered affiliations see end of article.

## Correspondence to

Gwen M C Masclee;  
g.masclee@erasmusmc.nl

## ABSTRACT

**Objectives:** Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO). However, previous studies did not adequately address bias and confounding. Our objective was to estimate the risk of OAC among patients with BO exposed to NSAIDs, statins and PPIs.

**Design:** Case-control study nested within a BO cohort.

**Setting:** Two primary care databases (the UK and the Netherlands (NL)).

**Participants:** Cases were adults  $\geq 18$  years of age with OAC or high-grade dysplasia (HGD) diagnosis  $\geq 1$  year after BO diagnosis. Controls were matched on age, sex, year of BO diagnosis and database.

**Exposure:** Drug use was assessed from BO diagnosis until matching date.

**Outcome measure:** Adjusted ORs with 95% CI were calculated by conditional logistic regression.

**Results:** Within the BO cohort (n=15 134), 45 OAC (UK: 40, NL: 5) and 12 HGD cases (NL: 12) were identified. ORa for OAC during NSAID use was 1.2 (95% CI 0.6 to 2.5) and during statin use for  $>3$  years 0.5 (95% CI 0.1 to 1.7). When including HGD cases (n=57), ORa for NSAID use was 0.9 (95% CI 0.5 to 1.8) and for statin use  $>3$  years 0.5 (95% CI 0.1 to 1.7). Higher doses of statins showed lower estimates for OAC and HGD, though not statistically significant. Low-dose aspirin and PPIs did not significantly decrease the risk of OAC and HGD.

**Conclusions:** In this population-based nested case-control study, use of NSAIDs, PPIs, low-dose aspirin or statins did not reduce the risk of HGD and OAC among patients with BO. These findings indicate that for an unselected group of patients with BO chemoprevention by use of drugs to reduce progression to HGD and OAC should not be directly considered as routine care.

## Strengths and limitations of this study

- Within a population-based cohort of incident Barrett's oesophagus (BO) patients derived from two European countries, and applying a common study protocol and drug exposure definition, the risk of development of oesophageal adenocarcinoma (OAC) was estimated during use of several drugs individually and concomitantly.
- We were able to minimise certain biases, for instance, due to availability of drug prescription data recall bias was avoided and by using a population-based approach selection bias was minimised.
- The small number of OAC cases that was identified limited the power for the duration analyses.
- We did not have detailed pathology information on the Barrett segment length or grade of dysplasia at cohort entry for every BO cohort member in both countries. This may have resulted from including patients with a short segment BO who may be at lower risk of developing high-grade dysplasia and OAC at the outset.

## INTRODUCTION

Barrett's oesophagus (BO) is a premalignant condition in which the squamous epithelium of the oesophagus is replaced by metaplastic columnar epithelium.<sup>1</sup> BO is considered a consequence of prolonged gastro-oesophageal reflux<sup>2</sup> and is the most important risk factor for development of oesophageal adenocarcinoma (OAC) via a stepwise pathway of low-grade and high-grade dysplasia (HGD). It is estimated that the risk of OAC is increased by approximately 30–125-fold in persons with BO,<sup>3</sup> and occurs in a small proportion of patients with BO yearly.<sup>4</sup> Endoscopic surveillance for BO is therefore recommended.<sup>2</sup>

In recent decades, the incidence of BO increased, accompanied by a marked increase

in OAC incidence in the USA and Western Europe.<sup>5 6</sup> However, estimates of OAC incidence among patients with BO vary substantially.<sup>7–10</sup> Generally, gastrointestinal cancers account for 25% of all cancers and approximately 4.9% of all deaths worldwide.<sup>11</sup> Death rates of most cancers decreased in recent years in contrast to the 3% increase in death rates of all oesophageal cancers (squamous cell carcinoma as well as adenocarcinoma) among males.<sup>11</sup> The age-standardised mortality rate for oesophageal cancer overall is 5.1/100 000 persons.<sup>6</sup> The need for effective prevention of oesophageal cancer, in general, is therefore warranted, particularly given the low 5-year survival rate of 13–17%.<sup>12</sup>

Several studies reported that use of non-steroidal anti-inflammatory drugs (NSAIDs), low-dose aspirin, statins and proton pump inhibitors (PPIs) may decrease the risk of OAC among patients with BO.<sup>13–21</sup> However, these studies were based on small, selected samples of OAC cases. PPIs are considered standard care for symptom relief in patients with BO, thus it was suggested that PPIs may decrease the risk of progression to HGD or OAC.<sup>20</sup> In contrast, other studies showed an increase in risk of OAC with PPI use, probably because the underlying treatment indication may be a risk factor for OAC rather than that PPIs being harmful for OAC among patients with BO.<sup>15 22</sup> Nevertheless, one cannot directly assume that PPIs, which are efficacious for treatment of erosive oesophagitis, will also be beneficial in the pathway from BO to OAC development. Two meta-analyses both including nine observational studies showed that the risk of oesophageal cancer<sup>14</sup> and HGD/OAC<sup>23</sup> among those who frequently use NSAIDs or aspirin was significantly lower compared with never users.<sup>14</sup> However, studies included in the earlier meta-analysis did not specifically include patients with BO. A pooled analysis on individual patient data confirmed the significant reduction in risk of OAC in patients with BO with NSAID prescriptions.<sup>24</sup> Two case-control studies observed an association between use of NSAIDs<sup>15</sup> and statins,<sup>15 25</sup> and the risk of OAC among patients with BO. Generalisation and extrapolation of results from the latter studies to the general population is, however, difficult as both studies were performed in US veterans.<sup>15 25</sup> Additionally, there was no adjustment for important risk factors of OAC progression such as alcohol use and smoking.<sup>15</sup> Nevertheless, a recent systematic review and meta-analysis showed a risk reduction in development of oesophageal cancer in general and OAC among patients with BO who took statins.<sup>26</sup>

Causality of an apparent association is generally supported by a dose-duration relationship.<sup>27</sup> However, studies to date neither reported a clear exposure definition free of recall bias<sup>13 16 24</sup> nor conducted dose-duration analyses. Finally, concerns have been raised about publication bias of these studies on chemoprevention of OAC in patients with BO.<sup>18</sup>

Thus, to what extent NSAIDs, low-dose aspirin, statins and PPIs may reduce the risk of OAC among patients with BO in clinical practice remains unknown.

Therefore, we conducted a matched case-control study to evaluate the risk of OAC among patients with BO associated with use of NSAIDs, low-dose aspirin, statins and PPIs.

## MATERIALS AND METHODS

### DATA sources

Two European population-based general practice registries served as data sources: (1) The Health Improvement Network (THIN) from the UK (1996–2011)<sup>28</sup> and (2) the Integrated Primary Care Information database (IPCI) from the Netherlands (NL, 1996–2012).<sup>29</sup> Both databases contain prospectively collected data that represent real-life practice. In the UK and in NL, all citizens are registered with a general practitioner (GP), who acts as a gatekeeper to secondary and tertiary medical care. THIN collects anonymised data on more than 3 million active patients from over 400 participating general practices, IPCI contains over 1.5 million active patients from 340 practices. For each individual patient all relevant medical information, from primary and secondary care, as well as additional information, including demographics and drug prescriptions, is documented in the medical record. Both data sources comply with European Union guidelines on the use of medical data for research.

THIN employs the READ clinical terminology system for coding medical diagnosis and symptoms,<sup>30</sup> whereas IPCI uses the International Classification for Primary Care (ICPC).<sup>31</sup> Information on drug prescriptions is captured in THIN with the Multilex product dictionary and British National Formulary (BNF) codes, whereas in IPCI, information on drug prescriptions is coded according to the WHO's Anatomical Therapeutic Chemical (ATC) classification.<sup>32</sup> Identification of the source and study population has been described previously.<sup>10</sup>

### Source population

The source population consisted of all patients aged  $\geq 18$  years who contributed data to the database between 1 January 1996 and 31 December 2011 (THIN) or March 2013 (IPCI). At least 1 year of available data prior to study entry were required to assess patient's medical history for exclusion criteria and risk factors. Follow-up started on 1 January 1996, or the date of reaching 18 years of age, or the date that 1 year of valid data were accrued within the database, whichever came later. Follow-up ended on the date of occurrence of study outcome (OAC), date of transfer out of the GP's practice, death, or last data drawn, whichever was earliest.

### Definition of BO

Patients with BO were identified using diagnosis codes; in THIN using corresponding READ codes (online supplementary appendix table 1).<sup>30</sup> In IPCI, each potential BO case was manually validated to confirm the histological diagnosis of BO and the date of first diagnosis or mentioning of BO in the clinical record. Patients were

excluded if they had a history of oesophageal cancer anytime before BO diagnosis and if they had a history of gastric cancer within 6 months after BO diagnosis. In IPCI, we could utilise free text from the medical record to assess the Barrett segment length and grade of dysplasia.

### Definition of OAC

In THIN, OAC cases were identified by READ codes (online supplementary appendix table 1). In IPCI, all patients with a record of ICPC codes D77.1 (malignant neoplasia of the oesophagus) and D77.0 (malignant neoplasia of the digestive tract—not specified), or with a record from free text search including word combinations of ‘oesophagus’, ‘cancer’, ‘carcinoma’, ‘malignancy’ or ‘neoplasia’, were identified. Similar to BO, all potential cases were manually validated for confirmation of the OAC diagnosis, date of first diagnosis and the type of carcinoma (squamous cell carcinoma, adenocarcinoma, or other types of carcinoma). Early cancer (HGD) was identified in IPCI also, but could not be assessed in THIN.

We only considered incident HGD or OAC cases: that is, if the date of diagnosis occurred after inclusion into the BO cohort and was at least 12 months after BO diagnosis. Cases occurring within 1 year from BO diagnosis were considered to be already existent at BO diagnosis date and in relation to the BO diagnostic work-up.

### Cases and controls selection

Two nested case–control studies were conducted assessing the risk of OAC for use of four drugs (NSAIDs, PPIs, statins and low-dose aspirin); one including only OAC cases and a second case–control study including HGD cases from IPCI as well.

Cases were adults diagnosed with OAC  $\geq 12$  months after BO diagnosis, because cases occurring within 1 year of BO diagnosis were considered to be existent and related to BO diagnostic work-up (eg, missed OAC at BO diagnosis). Index date was defined as date of first reporting of OAC diagnosis during follow-up. Controls were members of the incident BO cohort who did not develop OAC up to matching date. Controls were matched by incidence density sampling on age ( $\pm 5$  years), sex, year of BO diagnosis ( $\pm 1$  year) and database. We matched on year of BO diagnosis in order to account for any influence of guideline changes in endoscopic surveillance over calendar time.

### Drug exposure

Drug exposures of interest included four drug groups: NSAIDs, PPIs, statins and low-dose aspirin. They were assessed in terms of outpatient prescriptions for NSAIDs (including high-dose aspirin, ie,  $>325$  mg/day), PPIs, statins and low-dose aspirin (up to 325 mg/day) from BO diagnosis until OAC diagnosis. In order to compare the OR of NSAIDs, PPIs and statins to other drugs, we considered another group of medications, which served

as control. Antidepressants (selective serotonin re-uptake inhibitors (SSRIs)) are currently not known to be either positively or negatively associated with OAC.

Duration of prescriptions was calculated based on the prescribed quantity and dosing regimen. As the most likely preventive effect of drugs on cancer progression is through a cumulative mechanism, we calculated all duration and defined daily dose (DDD) values from date of BO diagnosis until index date. Duration was classified according to never use (reference category), cumulative use of less than 1 month, between 1 and 12 months,  $>12$  months (or if applicable 1–2 years; 2–3 years and  $>3$  years). Considering that PPIs are indicated as treatment for patients with BO, duration was classified as 0–6 months (reference category), 6–12 months, 1–2 years and  $>2$  years. Dose of exposure was classified using the ratio of prescribed daily dose compared with DDD using quartiles into categories ( $<0.8$ ,  $0.8$ – $1.2$ ,  $\geq 1.2$  DDD per day). As there is no DDD for low-dose aspirin, dose analysis was not performed for use of low-dose aspirin.

### Potential confounders

We considered as potential confounders: concurrent diagnosis of oesophagitis or gastritis within 1 year before BO diagnosis; hiatal hernia; smoking habits (non-smoker, ex-smoker, current smoker) and alcohol abuse (never, current, past).

### Statistical analyses

Baseline characteristics of cases and controls were described per database and compared using univariate conditional logistic regression.

To estimate the risk of HGD and OAC among patients with BO, matched and adjusted ORs (OR<sub>a</sub>) with 95% CIs were calculated using conditional logistic regression for both databases separately and as a pooled analysis on patient-level pooled data.

Potential confounders were included in the adjusted analysis (OR<sub>a</sub>) if they resulted in a change of more than 10% of the initial estimate. Time since BO diagnosis was forced into the adjusted model.

Subsequent analyses included dose–duration analyses. The risk of OAC and HGD–OAC was also assessed for concomitant use of NSAIDs, low-dose aspirin, statins and/or PPIs. Use of PPIs only was considered as reference category considering that PPIs are standard therapy for BO.

All analyses were performed using SAS V.9.2 (Cary, North Carolina, USA).

### Power calculation

Given an exposure prevalence of NSAIDs of 30%, statins of 22% or 36%, PPIs of 87% or 52% and low-dose aspirin of 25% among controls and a correlation of 0.5 between exposed and unexposed patients we have 80% power (with a type 1 error of 5%) to detect a true OR of OAC of 0.34 for NSAIDs, around 0.38–0.40 for statins, around 0.32–0.45 for PPIs and 0.29 for low-dose aspirin, which would be in concordance with previous studies.



## RESULTS

### Study population

From the source population of 7 570 765 patients in the UK and 1 496 276 patients in NL we identified 13 696 and 1438 incident BO cases, respectively. Men accounted for 63% (the UK) and 62% (NL) of patients with BO. Mean age at BO diagnosis was 64.8 (SD 13.8) years in the UK and 61.2 (SD 13.4) years in NL.

In the UK, we identified 40 incident OAC cases within the BO cohort (0.3%) to whom we could match 656 controls. Median number of controls per case was 17 (IQR 9–23). In NL we identified five incident OAC cases among the BO cohort (0.3%). These were matched to 76 control subjects, with a median of 5 controls per case (IQR 4–6). In addition, we identified 12 HGD cases, resulting in a second case–control set of 17 cases (5 OAC+12 HGD) matched to 753 controls (median 44 controls; IQR 6–61). **Figure 1** shows a flowchart of the study population. **Table 1** provides baseline characteristics of cases and controls. In the UK, a larger proportion of cases had a body mass index (BMI) over 25 kg/m<sup>2</sup>; 68% of cases and 59% of controls. In NL, the BMI of only one case within 1 year of OAC diagnosis was available (21.3 kg/m<sup>2</sup>). Controls had a mean BMI of 28.7 kg/m<sup>2</sup> (SD 4.7) in NL. Presence of oesophagitis or gastritis at time of BO diagnosis was more often seen in controls than in cases. In the UK, a hiatal hernia was more often present among cases, whereas the opposite was found in NL. In the UK, OAC cases were more likely to be current smokers than controls (OR 3.3; 95% CI 1.4 to 8.0), as seen in NL, though not significantly. Mean time from BO diagnosis until OAC diagnosis was 4.2 (SD 2.5) years in the UK and 3.5 (SD 0.8) years in NL.

### Drug exposure

**Table 2** provides characteristics of drug use from BO diagnosis until index date for cases and controls per database. Statins were used by 30% and 0% of OAC


cases; and by 36% and 22% of controls in the UK and NL, respectively. PPIs were used by OAC cases for a mean of 4.1 years (the UK) and 2.3 years (NL), and by controls for 2.9 years (the UK) and 1.9 years (NL). SSRI were used by 12.5% of OAC cases in the UK for a mean duration of 1 year, and by 7.6% of controls for a mean duration of 1.7 years. Low-dose aspirin was used by 26% of patients with BO in the UK and 6% of patients with BO in NL.

### Risk of oesophageal adenocarcinoma

To estimate the risk of OAC with use of NSAIDs, PPIs, statins and low-dose aspirin, a nested case–control study was conducted. From the adjusted model, on patient-level pooled data, exposure to NSAIDs and PPIs did not provide a significant decrease in the risk of OAC (**table 3**); for statins a non-significant effect was seen (ORa 0.7; 95% CI 0.4 to 1.5). This was seen in both databases separately as well (data not shown).

For NSAID use, ORs ranged between 1.1 and 1.4 for all duration categories; regarding dose-analysis, no difference in risk was found between higher and lower dosages (**table 4**). Although not significant, a dose–duration–response was seen for statins, with lower OR for longer duration of use compared with non-use of statins. Statin use  $\geq 1.2$  times higher compared to the recommended DDD resulted in an OR of 0.7 (95% CI 0.2 to 2.3). For PPIs an increase in OR was seen with prolonged duration, in the matched and in the adjusted analyses. PPIs used at highest dose showed an OR for HGD–OAC of 0.9 (95% CI 0.3 to 2.3). The ORs varied for duration categories of SSRI. No dose–response was seen for SSRI use. Use of low-dose aspirin provided ORs below 1 for OAC for matched and adjusted analysis, when considering the exposure at any time between BO diagnosis and OAC diagnosis; however, the 95% confidence limits still included the 1. When considering

**Figure 1** Flowchart of Barrett's oesophagus and oesophageal adenocarcinoma cases in the UK and the Netherlands. BO, Barrett's oesophagus; OAC, oesophageal adenocarcinoma; HGD, high-grade dysplasia; THIN, The Health Improvement Network; IPCI, Integrated Primary Care Information; PYs, person years.



**Table 1** Baseline characteristics of OAC cases and HGD cases in the UK and the Netherlands

	The UK				The Netherlands HGD–OAC			
	OAC case N (%)	Control N (%)	OR (95% CI)	p Value	HGD–OAC Case N (%)	HGD–OAC control N (%)	OR (95% CI)	p Value
Total	40 (100)	656 (100)			17 (100)	753 (100)		
OAC					5 (29.4)			
HGD					12 (70.6)			
Sex								
Male	33 (82.5)	597 (91)			11 (65)	524 (70)		
Female	7 (17.5)	59 (9)			6 (35)	229 (30)		
Mean age at index date (SD)	71.2 (10.4)	70.2 (9.0)			68.8 (8.2)	66.4 (8.8)		
Age group (years)								
<50	1 (2.5)	14 (2.1)			0 (0)	17 (2.3)		
51–65	8 (20)	149 (23)			6 (35)	338 (45)		
66–80	25 (62.5)	434 (66)			10 (59)	364 (48)		
>80	6 (15)	59 (9)			1 (5.9)	34 (4.5)		
BMI (kg/m <sup>2</sup> ) mean (SD)	27.7 (4.1)	26.9 (4)	1.1 (1.0 to 1.1)	0.210	28.9 (6.8)	26.4 (7.4)	1.1 (0.9 to 1.3)	0.500
BMI categories								
18–25	10 (25)	202 (31)			1 (5.9)	85 (11)		
<18	0 (0)	7 (1.1)	–	0.989	0 (0)	22 (2.9)	–	0.997
>25–30	19 (47.5)	269 (41)	1.5 (0.7 to 3.3)	0.329	2 (12)	156 (21)	1.3 (0.1 to 14.7)	0.995
>30–35	7 (17.5)	89 (14)	1.8 (0.7 to 5.0)	0.246	0 (0)	73 (9.7)	–	0.995
>35	1 (2.5)	31 (4.7)	0.8 (0.1 to 7.0)	0.866	1 (5.9)	14 (1.9)	6.1 (0.3 to 112.1)	0.993
Missing	3 (7.5)	58 (8.8)	1.0 (0.3 to 3.8)	0.992	13 (76)	403 (54)	2.0 (0.3 to 16.5)	0.994
Oesophagitis at BO diagnosis								
No	39 (97.5)	629 (95.9)			14 (82)	525 (70)		
Yes	1 (2.5)	27 (4.1)	0.6 (0.1 to 4.7)	0.633	3 (18)	228 (30)	0.5 (0.1 to 1.8)	0.299
Gastritis at BO diagnosis								
No	38 (95)	621 (94.7)			13 (76)	582 (77)		
Yes	2 (5)	35 (5.3)	1.2 (0.3 to 5.2)	0.808	4 (24)	171 (23)	1.5 (0.5 to 4.9)	0.516
Hiatal Hernia at BO diagnosis								
No	33 (82.5)	579 (88.3)			8 (47)	268 (36)		
Yes	7 (17.5)	77 (11.7)	1.7 (0.7 to 4.0)	0.259	9 (53)	485 (64)	0.7 (0.2 to 2.0)	0.487
Excessive alcohol use								
Never	17 (42.5)	370 (56)	Ref		17 (100)	713 (94.7)	–	0.991
Current	22 (55)	276 (42)	<b>2.0 (1.0 to 3.0)</b>	<b>0.048</b>	(0)	40 (5.3)		
Past	1 (2.5)	10 (1.5)	2.8 (0.3 to 23.4)	0.345				
Smoking								
Never	14 (35)	322 (49)	Ref		9 (53)	380 (50.5)	Ref	
Current	9 (22.5)	70 (11)	<b>3.3 (1.4 to 8.0)</b>	<b>0.009</b>	8 (47)	373 (49.5)	1.5 (0.5 to 4.5)	0.443
Past	17 (42.5)	264 (40)	1.7 (0.8 to 3.7)	0.155				
Index year								
1998	1 (2.5)	7 (1.1)			1 (5.9)	5 (0.7)		
2000	1 (2.5)	12 (1.8)			1 (5.9)	4 (0.5)		

Continued

Table 1 Continued

	The UK			The Netherlands			HGD–OAC		
	OAC case N (%)	Control N (%)	OR (95% CI)	p Value	HGD–OAC Case N (%)	HGD–OAC control N (%)	OR (95% CI)	p Value	
2001	3 (7.5)	24 (3.7)			1 (5.9)	7 (0.9)			
2002	2 (5)	10 (1.5)			2 (1.2)	9 (1.2)			
2003	2 (5)	15 (2.3)			1 (5.9)	3 (0.4)			
2004	4 (10)	94 (14)							
2005	7 (17.5)	128 (20)							
2006	1 (2.5)	20 (3)							
2007	2 (5)	30 (4.6)			1 (5.9)	22 (2.9)			
2008	6 (15)	107 (16)			1 (5.9)	66 (8.8)			
2009	4 (10)	72 (11)			1 (5.9)	49 (6.5)			
2010	4 (10)	85 (13)			2 (12)	163 (22)			
2011	3 (7.5)	52 (7.9)			5 (29.4)	374 (50)			
2012					1 (5.9)	51 (6.8)			
<i>Helicobacter pylori</i> infection									
No	40 (100)	603 (91.9)			17 (100)	714 (94.8)			
Yes	0 (0)	53 (8.1)			0 (0)	39 (5.2)			

BMI, body mass index; BO, Barrett's oesophagus; HGD, high-grade dysplasia; OAC, oesophageal adenocarcinoma.

duration analysis, the adjusted model provided for the prolonged duration of use (>1 year) an OR of 0.9 (95% CI 0.4 to 2.1).

Concomitant use of drugs of interest did not decrease the risk of OAC (table 5) compared with use of PPIs only, probably due to the smaller number of cases.

### Risk of high-grade dysplasia or oesophageal adenocarcinoma

In NL, we were able to retrieve HGD cases as well. When including these in the case definition, the effects were attenuated but in the same direction as the case–control study including OAC cases only. There was no significant decrease in the risk of HGD–OAC for exposure to NSAIDs, statins, PPIs and low-dose aspirin in the adjusted analysis (table 3). For NSAIDs, the OR increased with use of higher dosages (table 4). Again, for statins, a duration–response relationship with the longest duration yielding the lowest ORa (0.5; 95% CI 0.1 to 1.7) and an inverse association with increasing dose was observed, though none significant. For low-dose aspirin, PPI and SSRI use, no dose–response effects were shown.

The risk of HGD–OAC was 13% lower for concomitant use of NSAIDs+PPIs (ORa 0.9; 95% CI 0.3 to 2.2; table 5). None of the associations were statistically significant.

### DISCUSSION

In this population-based case–control study nested within a cohort of patients with BO, statin use may decrease the risk of OAC and HGD by up to 50%. PPIs did not reduce the risk of HGD and OAC, however, only when used at highest dose (eg, at least 1.2 times the recommended daily dose) a non-significant reduction may be present. In this unselected group of patients with BO, use of low-dose aspirin or NSAIDs was not associated with a decrease in risk of OAC. This is the first population-based study that looked at the preventive effect of these four different drugs used individually and also concomitantly.

The mechanism of OAC prevention is possibly related to inhibition of cyclo-oxygenase (COX)-2 production. Elevated levels of COX-2 in oesophageal epithelial cells have been observed in BO, and noted to increase with disease progression from BO to OAC.<sup>33</sup> In experimental studies, COX-2 inhibitors inhibited the growth of BO cells, potentially through suppression of basic fibroblast growth factor.<sup>34</sup> Another study confirmed that the end product of COX-2 conversion (prostaglandin E2) is reduced in patients with BO without HGD when using esomeprazole combined with higher doses (up to 325 mg/day) of cardiovascular aspirin.<sup>35</sup>

Statins exert antineoplastic properties in several ways. By inhibition of the 3-hydroxy-3-methylglutanyl coenzyme A reductase enzyme, subsequent modulation of growth signal transduction, cellular proliferation and cell death is achieved, which affects different organs.<sup>36</sup> In OAC cells particularly, statins inhibit cell proliferation and induce

**Table 2** Exposure characteristics of cases and controls in the UK and the Netherlands

	The UK		The Netherlands	
	OAC case	Control	HGD-OAC case	HGD-OAC control
	N=40	N=656	N=17	N=753
<b>NSAIDs</b>				
Exposed—N	11	148	2	102
Mean duration of use in days (SD)	205 (373)	218 (348)	18 (4)	49 (111)
Mean cumulative DDD (SD)	223 (393)	232 (383)	9 (2)	31 (79)
Median duration of use in days (IQR)	40 (20–178)	56 (28–203)	18 (15–20)	15 (10–60)
Median cumulative DDD (IQR)	40 (30–223)	56 (28–208)	9 (7–10)	10 (5–30)
<b>Statins</b>				
Exposed—N	12	236	3	123
Mean duration of use in days (SD)	648 (569)	996 (913)	570 (289)	409 (300)
Mean cumulative DDD (SD)	466 (353)	1000 (1258)	560 (191)	383 (331)
Median duration of use in days (IQR)	616 (109–966)	728 (350–1386)	450 (360–900)	330 (180–629)
Median cumulative DDD (IQR)	504 (110–775)	625 (243–1248)	450 (450–780)	270 (158–480)
<b>PPIs</b>				
Exposed—N	36	570	10	389
Mean duration of use in days (SD)	1500 (1134)	1071 (978)	615 (462)	442 (372)
Mean cumulative DDD (SD)	1425 (1247)	1060 (1123)	576 (402)	661 (1636)
Median duration of use in days (IQR)	1481 (644–2017)	766 (392–1458)	471 (240–1020)	315 (180–630)
Median cumulative DDD (IQR)	1223 (644–1772)	700 (364–1428)	471 (300–719)	360 (180–840)
<b>SSRIs</b>				
Exposed—N	5	50	0	15
Mean duration of use in days (SD)	369 (280)	613 (705)	–	743 (669)
Mean cumulative DDD (SD)	366 (283)	843 (1430)	–	737 (670)
Median duration of use in days (IQR)	252 (252–504)	381 (90–840)	–	600 (180–1740)
Median cumulative DDD (IQR)	252 (252–504)	339 (90–896)	–	596 (180–1740)
<b>Low-dose aspirin</b>				
Exposed—N	10	173	1	47
Mean duration of use in days (SD)	796 (606)	804 (733)	360	391 (301)
Mean cumulative DDD (SD)*	–	–	–	–
Median duration of use in days (IQR)	672 (448–1344)	600 (280–1096)	–	270 (180–540)
Median cumulative DDD (IQR)	–	–	–	–

\*Low-dose aspirin ( $\leq 325$  mg/day) has no DDD value.

DDD, defined daily dose; HGD, high-grade dysplasia; NSAIDs, non-steroidal anti-inflammatory drugs; OAC, oesophageal adenocarcinoma; PPIs, proton pump inhibitors; SSRIs, selective serotonin re-uptake inhibitors.

apoptosis<sup>37</sup> and limit the metastatic potential by reducing intracellular adhesion molecules.<sup>38</sup> However, statins also inhibit COX-2 expression in BO cells.<sup>39</sup>

Contrasting to other studies, we did not observe a significant preventive effect of NSAIDs, low-dose aspirin and statins with respect to the risk of HGD-OAC.<sup>13–14 24 40</sup> Based on the biological mechanisms, combined use of statins and NSAIDs or statins with low-dose aspirin may be expected to result in a greater risk reduction compared to either drug alone. We did not observe NSAIDs or low-dose aspirin with statins combined resulting in a significant risk reduction of OAC. This may be due to several reasons. First, despite our large BO cohort, the number of identified cases was smaller. Although we may have not have identified all potential OAC cases from the database, in a case-control study this is not necessary to obtain unbiased estimates. However, it limited the power of the study and resulted in statistically non-significant results. For assessment of concomitant drug exposure, in particular,

we did not reach statistical significance due to the lack of power, though this was not the primary aim of the study.

Our nesting cohort included all incident BO patients from the general population, and by matching on duration since BO diagnosis and excluding patients with prevalent BO, we removed any effect of selective survival bias, disease severity<sup>41</sup> or time window bias,<sup>42</sup> as those patients with BO with a longer follow-up are more likely to develop HGD or OAC. By doing so, observing any spurious associations was avoided. Second, we mitigated against immortal time bias<sup>43</sup> by defining the exposure period from BO diagnosis up to matching date, thus avoiding an overestimation of the preventive effect. The estimates from our study are likely more generalisable to the daily clinical practice in the general population, also including patients with less severe BO, that is, those with a shorter BO segment. A potential preventive effect of NSAIDs might therefore only be observed within selected high-risk subgroups.

**Table 3** Risk of OAC and HGD–OAC by drug class by duration on data pooled on patient-level

Exposure	Duration category	OAC						HGD–OAC					
		OAC Case N (%)	OAC Control N (%)	OR <sub>matched</sub> (95% CI)	p Value	OR <sub>adjusted</sub> * (95% CI)	p Value	Case N (%)	Control N (%)	OR <sub>matched</sub> (95% CI)	p Value	OR <sub>adjusted</sub> * (95% CI)	p Value
Total		45 (100)	732 (100)					57 (100)	1409 (100)				
NSAID	None	32 (71)	566 (77)	Ref		Ref		44 (77)	1159 (82)	Ref		Ref	
	Yes	13 (29)	166 (23)	1.3 (0.6 to 2.5)	0.492	1.2 (0.6 to 2.5)	0.532	13 (23)	250 (18)	1.0 (0.5 to 1.9)	1.000	0.9 (0.5 to 1.8)	0.876
	≤1 months	6 (11)	65 (9)	1.4 (0.6 to 3.6)	0.454	1.4 (0.6 to 3.5)	0.471	6 (11)	121 (9)	1.1 (0.4 to 2.6)	0.882	1.0 (0.4 to 2.5)	0.967
	>1 months to 1 year	5 (9)	72 (10)	1.2 (0.4 to 3.1)	0.768	1.1 (0.4 to 3.0)	0.817	5 (9)	98 (7)	0.9 (0.3 to 2.4)	0.836	0.8 (0.3 to 2.3)	0.737
	>1 year	2 (4)	29 (4)	1.2 (0.3 to 5.3)	0.837	1.1 (0.3 to 5.2)	0.859	2 (4)	31 (2)	1.1 (0.2 to 4.7)	0.934	1.0 (0.2 to 4.6)	0.970
Statins	None	33 (73)	479 (65)	Ref		Ref		42 (74)	1050 (75)	Ref		Ref	
	Yes	12 (27)	253 (35)	0.8 (0.4 to 1.5)	0.432	0.7 (0.4 to 1.5)	0.412	15 (26)	359 (25)	0.9 (0.5 to 1.7)	0.720	0.9 (0.5 to 1.7)	0.673
	≤1 months	1 (2)	6 (1)	2.1 (0.2 to 20.4)	0.511	2.0 (0.2 to 20.1)	0.561	1 (2)	7 (0)	2.2 (0.2 to 20.6)	0.487	2.1 (0.2 to 20.5)	0.520
	>1 months to 1 year	3 (7)	62 (8)	0.9 (0.3 to 3.2)	0.908	1.0 (0.3 to 3.4)	0.971	4 (7)	128 (9)	0.9 (0.3 to 2.8)	0.914	1.0 (0.3 to 2.8)	0.951
	>1 to 2 years	4 (9)	66 (9)	0.9 (0.3 to 2.7)	0.848	0.9 (0.3 to 2.6)	0.824	5 (9)	90 (6)	1.1 (0.4 to 2.9)	0.868	1.1 (0.4 to 2.8)	0.907
PPIs	>2 to 3 years	1 (2)	30 (4)	0.6 (0.1 to 4.9)	0.651	0.6 (0.1 to 4.7)	0.629	2 (4)	41 (3)	1.2 (0.3 to 5.3)	0.828	1.1 (0.2 to 4.9)	0.897
	>3 years	3 (7)	89 (12)	0.5 (0.1 to 1.7)	0.259	0.5 (0.1 to 1.7)	0.239	3 (5)	93 (7)	0.5 (0.1 to 1.8)	0.276	0.5 (0.1 to 1.7)	0.253
	0 to ≤6 months	5 (11)	103 (14)	Ref		Ref		11 (19)	450 (32)	Ref		Ref	
	Yes	40 (89)	629 (86)	1.1 (0.4 to 3.0)	0.814	1.1 (0.4 to 2.8)	0.911	46 (81)	959 (68)	1.0 (0.5 to 2.2)	0.917	0.9 (0.4 to 2.0)	0.855
	>6 to ≤12 months	6 (13)	169 (23)	1.9 (0.5 to 6.6)	0.502	2.0 (0.5 to 7.0)	0.299	7 (12)	158 (11)	1.7 (0.6 to 4.6)	0.293	1.7 (0.6 to 4.5)	0.312
	>12 to ≤24 months	9 (20)	151 (21)	1.8 (0.6 to 5.4)	0.672	1.7 (0.6 to 5.3)	0.328	10 (18)	227 (16)	1.7 (0.7 to 4.2)	0.255	1.6 (0.6 to 3.9)	0.326
	>24 months	5 (11)	162 (22)	2.1 (0.8 to 5.6)	0.476	1.9 (0.7 to 5.2)	0.207	27 (47)	377 (27)	1.7 (0.7 to 4.0)	0.204	1.5 (0.7 to 3.6)	0.327
SSRIs	None	40 (89)	679 (93)	Ref		Ref		52 (91)	1344 (95)	Ref		Ref	
	Yes	5 (11)	53 (7)	1.7 (0.6 to 4.7)	0.281	1.7 (0.6 to 4.6)	0.310	5 (9)	65 (5)	1.6 (0.6 to 4.2)	0.356	1.5 (0.6 to 4.1)	0.390
	≤1 months	0 (0)	3 (0)	–	0.992	–	0.992	0 (0)	3 (0)	–	0.988	–	0.988
	>1 months to 1 year	3 (7)	23 (3)	2.6 (0.7 to 9.2)	0.142	2.5 (0.7 to 8.9)	0.155	3 (5)	28 (2)	2.4 (0.7 to 8.6)	0.165	2.4 (0.7 to 8.4)	0.175
	>1 year	2 (4)	27 (4)	1.2 (0.3 to 5.5)	0.778	1.2 (0.3 to 5.4)	0.815	2 (4)	34 (2)	1.1 (0.2 to 4.9)	0.888	1.1 (0.2 to 4.7)	0.931
Low-dose aspirin	None	35 (78)	553 (76)	Ref		Ref		46 (81)	1189 (84)	Ref		Ref	
	Yes	10 (22)	179 (24)	0.9 (0.4 to 1.8)	0.702	0.8 (0.4 to 1.8)	0.662	11 (19)	220 (16)	0.9 (0.4 to 1.9)	0.799	0.9 (0.4 to 1.8)	0.764
	≤6 months	2 (4)	33 (5)	1.0 (0.2 to 4.2)	0.954	1.0 (0.2 to 4.3)	0.970	2 (4)	49 (3)	0.9 (0.2 to 3.7)	0.840	0.9 (0.2 to 3.8)	0.847
	>6 months to 1 year	0 (0)	26 (4)	–	–	–	–	1 (2)	36 (3)	–	–	–	–
	>1 year	8 (18)	120 (16)	1.0 (0.4 to 2.2)	0.920	0.9 (0.4 to 2.1)	0.844	8 (14)	135 (10)	0.9 (0.4 to 2.1)	0.867	0.9 (0.4 to 2.1)	0.805

\*Adjusted for duration of follow-up since BO diagnosis.

Cumulative use of drugs considered continuously (OR represents the change per day additional use).

BO, Barrett's oesophagus; HGD, high-grade dysplasia; NSAID, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors; OAC, oesophageal adenocarcinoma; SSRIs, selective serotonin re-uptake inhibitors.



**Table 4** Risk of OAC and HGD–OAC by drug class by daily dose on data pooled on patient-level

Drug exposure	Dose category	OAC only				HGD–OAC			
		Case N (%)	Control N (%)	OR <sub>matched</sub> (95% CI)	p Value	Case N (%)	Control N (%)	OR <sub>matched</sub> (95% CI)	p Value
Total		45 (100)	732 (100)			57 (100)	1409 (100)		
NSAID	None	32 (71)	566 (77)	Ref	–	44 (77)	1159 (82)	Ref	–
	<0.8 DDD per day	3 (7)	39 (5)	1.1 (0.3 to 3.7)	0.909	3 (5)	107 (8)	0.6 (0.2 to 2.2)	0.475
	≥0.8 to <1.2 DDD per day	4 (9)	74 (10)	0.9 (0.3 to 2.5)	0.783	4 (7)	84 (6)	0.8 (0.3 to 2.3)	0.633
	≥1.2 DDD per day	6 (13)	53 (7)	2.2 (0.8 to 5.6)	0.111	6 (11)	59 (4)	1.9 (0.8 to 5.0)	0.160
Statin	None	33 (73)	479 (65)	Ref	–	42 (74)	1050 (75)	Ref	–
	<0.8 DDD per day	8 (18)	126 (17)	0.9 (0.4 to 2.2)	0.880	9 (16)	174 (12)	1.0 (0.5 to 2.1)	0.959
	≥0.8 to <1.2 DDD per day	1 (2)	49 (7)	0.3 (0.05 to 2.6)	0.305	2 (4)	62 (4)	0.7 (0.2 to 3.1)	0.637
	≥1.2 DDD per day	3 (7)	78 (11)	0.7 (0.2 to 2.3)	0.519	4 (7)	123 (9)	0.8 (0.3 to 2.4)	0.731
PPI	None	5 (11)	103 (14)	Ref	–	11 (19)	450 (32)	Ref	–
	<0.8 DDD per day	9 (20)	168 (23)	0.9 (0.3 to 3.0)	0.914	11 (19)	196 (14)	1.1 (0.4 to 2.8)	0.910
	≥0.8 to <1.2 DDD per day	23 (51)	315 (43)	1.2 (0.4 to 3.4)	0.723	27 (47)	454 (32)	1.1 (0.5 to 2.6)	0.768
	≥1.2 DDD per day	8 (18)	146 (20)	1.1 (0.4 to 3.6)	0.822	8 (14)	309 (22)	0.9 (0.3 to 2.3)	0.813
SSRI	None	40 (89)	679 (93)	Ref	–	52 (91)	1344 (95)	Ref	–
	<0.8 DDD per day	1 (2)	8 (1)	3.0 (0.4 to 25.4)	0.317	1 (2)	8 (1)	3 (0.3 to 25.1)	0.321
	≥0.8 to <1.2 DDD per day	4 (9)	32 (4)	2.3 (0.7 to 7.1)	0.149	4 (7)	44 (3)	2.0 (0.7 to 6.0)	0.218
	≥1.2 DDD per day	0 (0)	13 (2)	–	0.987	0 (0)	13 (1)	–	0.987

DDD, defined daily dose; HGD, high-grade dysplasia; NSAID, non-steroidal anti-inflammatory drugs; OAC, oesophageal adenocarcinoma; PPIs, proton pump inhibitors; SSRIs, selective serotonin re-uptake inhibitors.

**Table 5** Risk of OAC and HGD–OAC for concomitant drug exposure of NSAIDs, LDA, statins and PPIs

Drug exposure*	OAC only					HGD–OAC						
	Case N (%)	Control N (%)	OR <sub>matched</sub> (95% CI)	p Value	OR <sub>adjusted</sub> model† (95% CI)	p Value	Case N (%)	Control N (%)	OR <sub>matched</sub> (95% CI)	p Value	OR <sub>adjusted</sub> model† (95% CI)	p Value
Total	45 (100)	732 (100)					57 (100)	1409 (100)				
PPI only	19 (42)	284 (39)	Ref	–	Ref	–	22 (39)	441 (31)	Ref	–	Ref	–
No NSAID or LDA or statin or PPI	3 (7)	65 (9)	0.9 (0.2 to 3.2)	0.837	0.9 (0.3 to 3.4)	0.919	9 (16)	407 (29)	1.0 (0.4 to 2.4)	0.947	1.1 (0.4 to 2.8)	0.839
NSAID+PPI	6 (13)	72 (10)	1.2 (0.5 to 3.2)	0.700	1.1 (0.4 to 3.0)	0.773	6 (11)	124 (9)	0.9 (0.4 to 2.4)	0.898	0.9 (0.3 to 2.2)	0.774
Statin+PPI	5 (11)	85 (12)	1.0 (0.4 to 2.9)	0.963	1.0 (0.3 to 2.8)	0.988	7 (12)	143 (10)	1.2 (0.5 to 3.1)	0.630	1.2 (0.5 to 3.0)	0.674
LDA+PPI	3 (7)	30 (4)	1.4 (0.4 to 5.5)	0.597	1.3 (0.4 to 5.2)	0.655	3 (5)	42 (3)	1.3 (0.4 to 4.9)	0.691	1.2 (0.3 to 4.7)	0.742
LDA+PPI+statin							2 (4)	104 (7)	0.4 (0.1 to 1.7)	0.202	0.4 (0.1 to 1.7)	0.198
NSAID+LDA+statin+PPI	4 (9)	41 (6)	1.2 (0.4 to 3.8)	0.744	1.2 (0.4 to 3.8)	0.760	4 (7)	43 (3)	1.2 (0.4 to 3.9)	0.727	1.2 (0.4 to 3.8)	0.745

\*Numbers do not add up due to drug exposure categories with only one exposed case, not shown in the Table.

†Adjusted for duration of follow-up since BO diagnosis.

BO, Barrett's oesophagus; HGD, high-grade dysplasia; LDA, low-dose aspirin; NSAID, non-steroidal anti-inflammatory drugs; OAC, oesophageal adenocarcinoma; PPIs, proton pump inhibitors.



Third, the inability to show a significant decrease in HGD and OAC risk for drug use may be explained by the distinct exposure definition that we applied. Contrasting with others,<sup>13 40</sup> we classified exposure cumulatively and performed dose–duration analyses rather than assessing drug exposure at a single moment. This, however, also limited the analyses by creating multiple exposure categories. Drug exposure changes over time, especially in the long time taken to develop cancer. Assessment of exposure on a fixed moment will result in bias that exaggerates the effect downwards, showing a protective effect while actually it has no effect.<sup>42</sup> A pooled analysis of observational studies demonstrated an inverse association between the risk of HGD–OAC and use of NSAIDs.<sup>24</sup> A prospective cohort study also showed a decreased HR of HGD–OAC for use of NSAIDs and statins, however, the study results were influenced by immortal time bias.<sup>17 44</sup> In that study, the majority of cases included HGD cases. In line with the other Dutch study,<sup>17</sup> when we included HGD cases the risk of HGD–OAC was lower than when including OAC cases only. The preventive effect is possibly achieved in the pre-malignant stage of dysplasia–development rather than that of adenocarcinoma. It is, however, difficult to disentangle drug exposure effects in three different risk periods: induction (dysplasia), latent (between dysplasia and cancer) and disease period (cancer). Ideally, this requires knowledge on exact timing of the first aberrant Barrett's cell and subsequent stages towards HGD and OAC progression develop.

The fourth explanation for not observing a preventive effect may be the exposure prevalence. Regarding NSAID exposure prevalence, we could not capture over-the-counter use of NSAIDs. During the study period, NSAIDs and PPIs were reimbursable in the NL and the UK, and thus we assume that over-the-counter use of NSAIDs and PPIs did not confound the results to a great extent. Prevalence of PPI (81%) and statin (26%) exposure in our study is, however, comparable with other studies and is therefore unlikely to have limited our power.<sup>17 45</sup>

A large prospective US cohort study showed a tremendous protective effect of NSAIDs on OAC risk.<sup>40</sup> However, NSAID exposure was assessed in a personal interview and classified very broadly by NSAIDs used at least once a week for 6 months.<sup>40</sup> If the preventive effect of NSAIDs were as high as reported (up to 80%), a duration–dose–response effect is to be expected. This study failed to demonstrate an inverse association between duration of NSAID use and the risk of OAC. In fact, the opposite was observed; the most protective effect was seen for the shortest duration,<sup>40</sup> contradicting a causal association.<sup>27 46</sup> A pooled analysis also could not demonstrate that prolonged duration of NSAID use was associated with a lower risk of OAC.<sup>24</sup> Additionally, heterogeneity between studies was observed,<sup>24</sup> which emphasises the controversy around clinically effective chemoprevention with NSAIDs.

The preventive effect of statins is shown in several studies,<sup>13 17</sup> yielding a risk reduction of OAC up to 48% for statin use >1 year.<sup>15</sup> However, in a meta-analysis, the

risk reduction of OAC among patients with BO was only seen when studies were included that assessed drug exposure by patient interview, which may be prone to recall bias, whereas the risk reduction was not significant, including studies that assessed drug exposure by use of prescription/dispensing data in electronic medical records.<sup>26</sup> Also, for statins, the most pronounced effect was seen when HGD was included.<sup>16</sup> Results from the latter study should be interpreted with caution as drug exposure was classified by self-report as 'ever' instead of a duration classification. A recent case–control study, using a GP database from the UK, showed that statins may also decrease the risk of OAC and oesophago-gastric junctional adenocarcinoma in the general population.<sup>47</sup> The chemopreventive action of statins was more pronounced when combined with low-dose aspirin in a previous study.<sup>13</sup> It could be that the preventive effect of statins is explained by other risk factors common to statin users and patients with OAC, such as cardiovascular risk factors or lifestyle changes: smoking, exercise and weight.<sup>47</sup> Also it may be that patients with BO died from vascular diseases rather than of cancer-related causes or before HGD or OAC developed.<sup>48</sup> In our study, statin users were less likely to be current smokers, were of older age and were more often men. However, whether lifestyle changes due to comorbid cardiovascular diseases and initiating statin therapy may have resulted in healthier behaviour, and subsequent OAC risk reduction, is open to debate.

Strengths of the current study include the scale and setting by combining healthcare data from two European countries with comparable GP databases and applying a common study protocol and drug exposure definition. The nested case–control design in a well-defined population representing the general population minimised selection bias. While previous studies may have suffered from recall bias or the lack of detailed drug prescription data, we were able to estimate the risk of HGD and OAC within patients with BO during drug use in the general population. Although our analysis may be limited by the small number of cases in the dose–duration analyses, partly due to the fact that we only included incident cases (diagnosed  $\geq 1$  year after BO diagnosis), our study is unlikely to suffer from biases (immortal time bias, time window bias) and confounding (disease severity) by matching on important risk factors. Matched and adjusted analyses were in line with each other suggesting that there was little confounding.

A limitation of the study is the lack of detailed pathology information on the Barrett segment length and grade of dysplasia, as is current practice for risk stratification of patients with BO. This may have resulted in misclassification of BO and OAC. However, the 1-year risk of OAC after BO diagnosis, excluding OAC cases within 1 year after BO diagnosis, was 0.086% (95% CI 0.04 to 0.17) in the current study,<sup>10</sup> which is similar to other population-based studies.<sup>4 49 50</sup> Because we could not verify the diagnosis of BO against a clinical prespecified

standard and did not review biopsy specimens, it is also possible that we inadvertently included patients at very low risk of developing OAC. In the Dutch database, we could search through the medical records and noted that 8% had a segment length <2 cm, 13.7% between 2 and 3 cm, 11.8% longer than 3 cm, whereas for 60% of BO controls the length was not mentioned. Regarding the grade of dysplasia at time of BO diagnosis, 45% of controls had no dysplasia; there was low grade dysplasia in 6% of patients with BO, indefinite for dysplasia in 1.8%, whereas no information on dysplasia grade was available in 46% of controls. Of the cases that developed HGD or OAC, 24% had a prior histology report of low-grade dysplasia. In the Dutch database we could utilise all free text entered in the medical record, enabling us to look for more detailed information in clinical letters, resulting in higher proportion of risk factors, such as presence of oesophagitis and a hiatal hernia at time of BO diagnosis as compared with the UK database, in which we relied on diagnosis codes. We tried to address confounding-by-indication and time-window bias by matching on age, sex and year of BO diagnosis.<sup>42</sup> This is seen by the fact that individual risk factors did not increase the OAC risk and adjustment for these confounders did not change the estimate by  $\geq 10\%$ . The observation that PPIs appear to increase the risk of OAC is explained by the treatment indication being a risk factor for OAC, reverse causation and the phenomenon of 'channeling', where high-risk patients are being prescribed PPIs whereas low-risk patients are being prescribed with lower doses or not at all,<sup>15 22 47 51 52</sup> a phenomenon often seen with PPIs and upper gastrointestinal bleeding.<sup>53</sup> It could also be that the effect of PPIs is apparent after minimally 2 years of use,<sup>15 20</sup> an observation that was not significant in our study.

In conclusion, in this population-based nested case-control study, use of NSAIDs, PPIs, low-dose aspirin or statins did not reduce the risk of HGD and OAC among patients with BO. These findings indicate that for an unselected group of patients with BO, chemoprevention by use of drug to reduce progression should not be considered directly as routine care.

#### Author affiliations

<sup>1</sup>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>2</sup>Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>3</sup>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands

**Contributors** GMC contributed to study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript. PMC contributed to study concept and design; interpretation of data; drafting of the manuscript. MCWS contributed to critical revision of the manuscript for important intellectual content. EJK contributed to analysis and interpretation of data; critical revision of the manuscript for important intellectual content. MCJMS contributed to study concept and design; acquisition of data; analysis and interpretation of data; critical revision of the manuscript for important intellectual content; obtained funding; study supervision. All authors approved the final version of the manuscript.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** EJK has, since completion of this research, started working for the medical board of Erasmus University Medical Center. MCJMS is coordinating a research group that has unconditional research grants from Pfizer, Novartis and Lilly; none related to this research.

**Ethics approval** The Scientific and Ethical Advisory Boards of both databases (THIN and IPIC) approved the study.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

#### REFERENCES

1. Spechler SJ, Souza RF. Barrett's esophagus. *N Engl J Med* 2014;371:836–45.
2. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. *Am J Gastroenterol* 2008;103:788–97.
3. Soleymani-Dodaran M, Logan RF, West J, *et al.* Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. *Gut* 2004;53:1070–4.
4. de Jonge PJ, van Blankenstein M, Looman CW, *et al.* Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. *Gut* 2010;59:1030–6.
5. Desai TK, Krishnan K, Samala N, *et al.* The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. *Gut* 2012;61:970–6.
6. Globocan 2008 Worldwide Cancer Incidence M, Prevalence and Disability-adjusted life years (DALYs) (accessed 11 Jul 2014).
7. Yousef F, Cardwell C, Cantwell MM, *et al.* The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. *Am J Epidemiol* 2008;168:237–49.
8. Sikkema M, de Jonge PJ, Steyerberg EW, *et al.* Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2010;8:235–44; quiz e32.
9. Rastogi A, Puli S, El-Serag HB, *et al.* Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. *Gastrointest Endosc* 2008;67:394–8.
10. Masclee GM, Coloma PM, de Wilde M, *et al.* The incidence of Barrett's esophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off. *Aliment Pharmacol Ther* 2014;39:1321–30.
11. WHO Global Health Observatory Data Repository. Cause-specific mortality, 2008: WHO region by country. <http://apps.who.int/gho/data/node.main.887?lang=en> (accessed 18 Oct 2013).
12. Cancer Research UK. Oesophageal cancer survival statistics. <http://www.cancerresearchuk.org/cancer-info/cancerstats/types/oesophagus/survival/#Trends> (accessed 18 Oct 2013).
13. Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett's esophagus is associated with a reduced incidence of oesophageal adenocarcinoma. *Eur J Gastroenterol Hepatol* 2012;24:917–23.
14. Corley DA, Kerlikowske K, Verma R, *et al.* Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. *Gastroenterology* 2003;124:47–56.
15. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. *Gastroenterology* 2010;138:2260–6.
16. Kantor ED, Onstad L, Blount PL, *et al.* Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. *Cancer Epidemiol Biomarkers Prev* 2012;21:456–61.
17. Kastelein F, Spaander MC, Biermann K, *et al.* Nonsteroidal anti-inflammatory drugs and statins have chemopreventive effects in patients with Barrett's esophagus. *Gastroenterology* 2011;141:2000–8; quiz e13–4.

18. Abnet CC, Freedman ND, Kamangar F, *et al.* Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. *Br J Cancer* 2009;100:551–7.
19. Rothwell PM, Fowkes FG, Belch JF, *et al.* Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 2011;377:31–41.
20. Singh S, Garg SK, Singh PP, *et al.* Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. *Gut* 2014;63:1229–37.
21. Sivarasan N, Smith G. Role of aspirin in chemoprevention of oesophageal adenocarcinoma: a meta-analysis. *J Dig Dis* 2013;14:222–30.
22. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. *Gut* 2006;55:1538–44.
23. Zhang S, Zhang XQ, Ding XW, *et al.* Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. *Br J Cancer* 2014;110:2378–88.
24. Liao LM, Vaughan TL, Corley DA, *et al.* Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. *Gastroenterology* 2012;142:442–52.e5; quiz e22–3.
25. Nguyen T, Khalaf N, Ramsey D, *et al.* Statin use is associated with a decreased risk of Barrett's esophagus. *Gastroenterology* 2014;147:314–23.
26. Singh S, Singh AG, Singh PP, *et al.* Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013;11:620–9.
27. Rothman KJ, Greenland S, Lash TL. *Causation and causal inference*. Modern epidemiology. 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008.
28. Lewis JD, Schinnar R, Bilker WB, *et al.* Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. *Pharmacoepidemiol Drug Saf* 2007;16:393–401.
29. Vlug AE, van der Lei J, Mosseveld BM, *et al.* Postmarketing surveillance based on electronic patient records: the IPCI project. *Methods Inf Med* 1999;38:339–44.
30. Booth N. What are the read codes? *Health Libr Rev* 1994;11:177–82.
31. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. *Fam Pract* 1992;9:330–9.
32. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. <http://www.whocc.no/atcddd/> (accessed 4 Apr 2013).
33. Wilson KT, Fu S, Ramanujam KS, *et al.* Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. *Cancer Res* 1998;58:2929–34.
34. Buttar NS, Wang KK, Anderson MA, *et al.* The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. *J Natl Cancer Inst* 2002;94:422–9.
35. Falk GW, Buttar NS, Foster NR, *et al.* A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. *Gastroenterology* 2012;143:917–26.e1.
36. Lochhead P, Chan AT. Statins and colorectal cancer. *Clin Gastroenterol Hepatol* 2013;11:109–18; quiz e13–4.
37. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. *Am J Gastroenterol* 2008;103:825–37.
38. Sadaria MR, Reppert AE, Yu JA, *et al.* Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. *J Thorac Cardiovasc Surg* 2011;142:1152–60.
39. Konturek PC, Burnat G, Hahn EG. Inhibition of Barrett's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. *J Physiol Pharmacol* 2007;58(Suppl 3):141–8.
40. Vaughan TL, Dong LM, Blount PL, *et al.* Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's esophagus: a prospective study. *Lancet Oncol* 2005;6:945–52.
41. Delgado-Rodriguez M, Llorca J. Bias. *J Epidemiol Community Health* 2004;58:635–41.
42. Suissa S, Dell'aniello S, Vahey S, *et al.* Time-window bias in case-control studies: statins and lung cancer. *Epidemiology* 2011;22:228–31.
43. Suissa S. Immortal time bias in pharmaco-epidemiology. *Am J Epidemiol* 2008;167:492–9.
44. Azoulay L, Suissa S. Immortal person-time bias in relation to the use of nonsteroidal anti-inflammatory drugs and statins in the prevention of esophageal cancer in patients with Barrett's esophagus. *Gastroenterology* 2012;142:e20–1; author reply e21.
45. Kastelein F, Spaander MC, Steyerberg EV, *et al.* Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. *Clin Gastroenterol Hepatol* 2013;11:382–8.
46. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. *Am J Public Health* 2005;95(Suppl 1):S144–50.
47. Alexandre L, Clark AB, Bhutta HY, *et al.* Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. *Gastroenterology* 2014;146:661–8.
48. Moayyedi P, Burch N, Akhtar-Danesh N, *et al.* Mortality rates in patients with Barrett's oesophagus. *Aliment Pharmacol Ther* 2008;27:316–20.
49. Bhat S, Coleman HG, Yousef F, *et al.* Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. *J Natl Cancer Inst* 2011;103:1049–57.
50. Hvid-Jensen F, Pedersen L, Drewes AM, *et al.* Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med* 2011;365:1375–83.
51. Strom BL, Kimmel SE, eds. *Textbook of pharmacoepidemiology*. Chichester: John Wiley & Sons, 2006.
52. Hvid-Jensen F, Pedersen L, Funch-Jensen P, *et al.* Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. *Aliment Pharmacol Ther* 2014;39:984–91.
53. Masclee GM, Valkhoff VE, Coloma PM, *et al.* Risk of upper gastrointestinal bleeding from different drug combinations. *Gastroenterology* 2014;147:784–92.e9, quiz e13–4.